CS
LEGN icon

Candriam SCA’s Legend Biotech LEGN Stock Holding History

Candriam SCA’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.6M Buy
504,924
+34,632
+7% +$934K 0.07% 238
2026
Q1 		$8.51M Buy
470,292
+208,477
+80% +$3.97M 0.04% 306
2025
Q4 		$5.69M Hold
261,815
– – 0.03% 361
2025
Q3 		$8.54M Hold
261,815
– – 0.04% 295
2025
Q2 		$9.29M Buy
261,815
+39,983
+18% +$1.3M 0.05% 260
2025
Q1 		$7.53M Sell
221,832
-171,620
-44% -$6.15M 0.05% 270
2024
Q4 		$12.8M Buy
393,452
+27,465
+8% +$1.14M 0.07% 228
2024
Q3 		$17.8M Buy
365,987
+104,952
+40% +$5.59M 0.1% 197
2024
Q2 		$11.6M Buy
261,035
+40,003
+18% +$1.85M 0.07% 237
2024
Q1 		$12.4M Sell
221,032
-20,000
-8% -$1.21M 0.08% 232
2023
Q4 		$14.5M Buy
241,032
+10,000
+4% +$634K 0.1% 208
2023
Q3 		$15.5M Hold
231,032
– – 0.11% 175
2023
Q2 		$15.9M Buy
231,032
+115,006
+99% +$7.51M 0.12% 187
2023
Q1 		$5.15M Hold
116,026
– – 0.04% 355
2022
Q4 		$5.79M Hold
116,026
– – 0.04% 356
2022
Q3 		$4.73M Buy
+116,026
New +$5.45M 0.03% 389

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Candriam SCA's LEGN Position: Q2 2026 in Review

Candriam SCA increased its Legend Biotech (LEGN) stake by 7.4% in Q2 2026, buying an estimated $934K and bringing the position to 504,924 shares worth $14.6M. The position accounts for 0.07% of the portfolio, ranked #238.

Candriam SCA first reported a position in LEGN in Q3 2022 and has held it in 16 quarters since. The position peaked at $17.8M in Q3 2024. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Candriam SCA held 504,924 shares of Legend Biotech worth $14.6M as of Q2 2026.
  • Candriam SCA bought 34,632 Legend Biotech shares in Q2 2026, an estimated $934K.
  • Legend Biotech made up 0.07% of Candriam SCA's portfolio in Q2 2026, its #238 holding.
  • Candriam SCA first reported a position in Legend Biotech in Q3 2022 and has held it in 16 quarters since.
  • Candriam SCA's Legend Biotech position peaked at $17.8M in Q3 2024.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.